Enlivex (ENLV) EBIT Margin (2022 - 2025)
Enlivex (ENLV) posted quarterly EBIT Margin of 92.54% for Q1 2025, up 334.0% year-over-year from 21.32% in Q1 2024, and up 283.59% quarter-over-quarter from 50.4% in Q4 2024.
Enlivex (ENLV) EBIT Margin (2022 - 2025) Analysis & Trends
Enlivex's EBIT Margin history runs 4 years deep, the most recent figure standing at 92.54% for Q1 2025.
- In Q1 2025, EBIT Margin rose 334.0% year-over-year to 92.54%; the TTM figure through Mar 2025 stood at 62.08% (up 194867.0% YoY), while the FY2024 annual figure was 43.01%, down 5667.0% from the prior year.
- EBIT Margin for Q1 2025 stood at 92.54%, up from 50.4% in the prior quarter.
- The five-year high for EBIT Margin was 92.54% in Q1 2025, with the low at 50.4% in Q4 2024.
- The 4-year median for EBIT Margin is 83.06% (2023), against an average of 41.71%.
- The sharpest annual moves came in 2023 and 2024: EBIT Margin jumped 1053 bps in 2023, then tumbled 320 bps in 2024.
- Enlivex's EBIT Margin stood at 77.79% in 2022, then sank by 161 bps to 47.2% in 2023, then fell by 7 bps to 50.4% in 2024, then surged by 284 bps to 92.54% in 2025.
- Business Quant data shows ENLV's EBIT Margin at 92.54% in Q1 2025, 50.4% in Q4 2024, and 89.19% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 19.75% |
| 10 | Enlivex | 4.49 Mn | -1.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 92.54% |
| Dec 31, 2024 | -50.40% |
| Mar 31, 2024 | 89.19% |
| Dec 31, 2023 | -47.20% |
| Mar 31, 2023 | 88.32% |
| Mar 31, 2022 | 77.79% |